期刊文献+

双肾上腺皮质激素样激酶-1与细胞周期蛋白D1在结直肠癌组织中的表达及临床意义 被引量:4

Expression and clinical significance of doublecortin and CaM kinase-like-1 and cyclin D1 in colorectal carcinomas
下载PDF
导出
摘要 目的:探讨双肾上腺皮质激素样激酶-1(EgJLKl)与细胞周期蛋白D1(cyclin D1)在结直肠癌组织中的表达及其临床意义。方法:采用免疫组织化学S-ABC法检测59例结直肠癌组织和28例结直肠良性病变组织中DCI。K1及cyclinD1的表达及分布。结果:DCLK1及cyclin D1在结直肠癌组织中的表达明显高于结直肠良性病变组织,平均光密度值(AOD)为0.423±0.021及0.386±0.042;而在结直肠良性病变组织中其阳性反应的平均光密度值为0.267±0.053及0.21l±0.026,差异具有统计学意义。DCLK1及cyclinD1的阳性表达与患者的年龄、性别、肿瘤分化程度和DUCKs分期无关,而与组织良性或恶性、肿瘤的大小及淋巴结转移相关。结论:结直肠癌组织中DCLKl及cyclinD1的高表达可能与结直肠癌的发生、发展、转移相关,可作为结直肠癌转移及预后监测的一项重要指标。 Objective: To explore the expression and clinical significance of doublecortin and CaM kinasedike-1 (DCLK1) and cyclin D1 in coloreetal carcinomas. Methods: Expression and distribution of DCLK1 and cyclin D1 were detected by S-ABC immunohistochemistry in 59 colorectal carcinomas and 28 benign lesions on colorectus. Results: in the colorectal carcinomas, DCLK1 and cyclin D1 expression was up-regulated, AOD were 0. 423 ± 0. 021 and 0. 386±0. 042; in benign lesions of colorectus, AOD were 0. 267±0. 053 and 0. 211±0. 026, and the difference was statistically significant. There was no relation among positive-reaction of DCLK1, cyclin D1 and the patient's age, sexuality, tumor differentiation and DUCKs stage. However, they were correlated with histologic type, tumor diameter and lymph node metastasis. Conclusion: I)CLK1 and cyclin D1 over-expression may play a role in the carcinogenesis, development metastasis and relapse of colorectal cancer. They could be used as a significant monitoring marker of metastasis and prognostic supervision of colorectal cancer in clinical practice.
出处 《解剖学杂志》 CAS CSCD 北大核心 2016年第2期166-168,182,共4页 Chinese Journal of Anatomy
基金 云南省教育厅基金(2015J117)
关键词 结直肠癌 双肾上腺皮质激素样激酶-1 细胞周期蛋白D1 colorectal carcinoma doublecortin and CaM kinase-like-1 cyclin D1
  • 相关文献

参考文献1

二级参考文献49

  • 1Available online: http://www.cancer.org/acs/groups/cid/ documents/webcontent/003096-pdf.pdf.
  • 2American Cancer Society. Colorectal Cancer Facts & Figures. Atlanta, Georgia: American Cancer Society, 2011-2013.
  • 3Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 1979;189:496-502.
  • 4De Dosso S, Sessa C, Saletti P. Adjuvant therapy for colon cancer: present and perspectives. Cancer Treat Rev 2009;35:160-6.
  • 5Kopetz S, Freitas D, Calabrich AF, et al. Adjuvant chemotherapy for stage II colon cancer. Oncology (Williston Park) 2008;22:260-70; discussion 270, 273,275.
  • 6Marshall JL, Hailer DG, de Gramont A, et al. Adjuvant Therapy for Stage H and HI Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. Gastrointest Cancer Res 2007;1:146-54.
  • 7de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/ LV in the adjuvant treatment of stage II and stage HI colon cancer: Efficacy results with a median follow-up of 4 years. J Clin Onco12005;23:abstr 3501.
  • 8Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84.
  • 9Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001 ;414:105-11.
  • 10Lin SP, Lee YT, Wang JY, et al. Survival of cancer stem cells under hypoxia and serum depletion via decrease in PP2A activity and activation of p38-MAPKAPK2-Hsp27. PLoS One 2012;7:e49605.

共引文献8

同被引文献34

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部